XVIVO Heart Assist Transport™
Donor Heart Preservation
Clinical InvestigationActive (First patient enrolled in US PRESERVE CAP study, CE approval delayed)
Key Facts
Indication
Donor Heart Preservation
Phase
Clinical Investigation
Status
Active (First patient enrolled in US PRESERVE CAP study, CE approval delayed)
Company
About XVIVO
XVIVO Perfusion AB is a publicly traded Swedish medtech leader with a mission to ensure 'nobody should die waiting for a new organ.' The company has achieved commercial success by establishing its machine perfusion devices and PERFADEX® Plus solution as standards of care in lung transplantation and expanding into kidney and liver preservation. Its strategy focuses on leveraging its integrated hardware-and-chemistry platform to expand into new organ types, like the heart, and deepen its service offerings to become a full-service partner to transplant centers worldwide.
View full company profile